%20(2).png){kind=logo}
For over 30 years, Richard Pops has led Alkermes from a small private entity to a $4.3B publicly traded company. His unwavering commitment to addressing serious mental illnesses and substance use disorders has driven breakthroughs for the industry.
So, how does a CEO transform a neuroscience-focused life science company into a pioneering leader in treating stigmatized conditions?
Ostro CEO Chase Feiger, M.D., sits down with Richard Pops for Forbes to get an in-depth review of Alkermes’ approach and innovative work addressing patients' complex needs.
.svg)